The National Institute for Health and Care Excellence (NICE) published draft guidance recommending avelumab (Bavencio, Merck Serono) for the treatment of certain forms of bladder cancer. Adults with ...
Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...
We performed whole-transcriptome sequencing (n = 188) and exon capture DNA sequencing (n = 208) on pretreatment tumors from the CALGB 90601 randomized trial of gemcitabine/cisplatin plus bevacizumab ...
Add Yahoo as a preferred source to see more of our stories on Google. At the 2025 European Society of Medical Oncology (ESMO) Congress, held from October 17–21, results from the Phase III RC48-C016 ...
Inlexzo is approved for BCG-unresponsive NMIBC with CIS, offering a new treatment option for patients with limited alternatives. The SunRISe-1 trial showed an 82% complete response rate, with 51% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results